Sugi Predict

Sugi Predict / Targets / PSMD13

PSMD13

26S proteasome non-ATPase regulatory subunit 13 · Q9UNM6 · PSMD13 on Sugi Atlas →

5,920 patent compounds predicted against PSMD13, 4,539 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL3170187 SCHEMBL3170187 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL3170843 SCHEMBL3170843 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20

Clinical trials — most relevant to PSMD13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma PHASE2COMPLETED
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis PHASE1/PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Effect of Diaphragm Stimulation During Surgery nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
A Natural History Study of Angelman Syndrome nanRECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Phenotype/Genotype Correlations in Neuromuscular Disorders nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMD13 binder may also engage these)

ProteinNameSimilarity
Q5E964 — 1.000 Q5E964 →
Q9WVJ2 — 0.999 Q9WVJ2 →
P84169 — 0.998 P84169 →
B0BN93 — 0.998 B0BN93 →
Q8RWF0 — 0.985 Q8RWF0 →
Q8GYA6 — 0.982 Q8GYA6 →
Q68FS2 — 0.981 Q68FS2 →
Q5R648 — 0.980 Q5R648 →
Q5ZLA5 — 0.978 Q5ZLA5 →
Q6P0H6 — 0.978 Q6P0H6 →
Q3SZA0 — 0.977 Q3SZA0 →
O88544 — 0.977 O88544 →
Q641X8 — 0.976 Q641X8 →
A7Y521 — 0.974 A7Y521 →
Q4R5E6 — 0.974 Q4R5E6 →
B5DGH9 — 0.974 B5DGH9 →
Q3B8M3 — 0.974 Q3B8M3 →
F1QGH9 — 0.973 F1QGH9 →
EIF3E Eukaryotic translation initiation factor 3 subunit E 0.973 landscape →
COPS4 COP9 signalosome complex subunit 4 0.973 landscape →
Q5R8K9 — 0.972 Q5R8K9 →
P60229 — 0.972 P60229 →
Q4R6G8 — 0.972 Q4R6G8 →
Q6DRI1 — 0.972 Q6DRI1 →
Q6P7L9 — 0.972 Q6P7L9 →
Q05AY2 — 0.971 Q05AY2 →
Q5RF54 — 0.971 Q5RF54 →
Q3T102 — 0.970 Q3T102 →
Q94899 — 0.969 Q94899 →
Q28C65 — 0.969 Q28C65 →